Unicycive Therapeutics, Inc.
UNCY
$0.6379
$0.0081.27%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 46.44% | 23.92% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.74% | 48.15% | |||
| Operating Income | 13.74% | -48.15% | |||
| Income Before Tax | 102.65% | -425.51% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 102.65% | -425.51% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 102.65% | -425.51% | |||
| EBIT | 13.74% | -48.15% | |||
| EBITDA | 13.76% | -48.18% | |||
| EPS Basic | 102.16% | -341.65% | |||
| Normalized Basic EPS | 102.36% | -342.01% | |||
| EPS Diluted | 75.34% | -341.65% | |||
| Normalized Diluted EPS | 102.28% | -342.01% | |||
| Average Basic Shares Outstanding | 10.50% | 18.86% | |||
| Average Diluted Shares Outstanding | 17.14% | 18.86% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||